Medical Doctor Program year 2021 Source: CMS Open Payments, 2026 publication

Susan Boyer

Psychiatry Saint Louis, MO Medical Doctor

NPI 1780733832 CMS profile 897998

8301 Maryland Ave Ste 330, Suite 100, Saint Louis, MO 63105

Open in the dashboard

General payments

$260

19 records reported · program year 2021

Research payments

$0

Paid to them · None reported · program year 2021

Ownership & investment interest

$0

None reported

Through program year 2021, Susan Boyer of Saint Louis, MO is reported in the CMS Open Payments database as having received $260 across 19 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 48th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

1 row
Year Kind Relative to this record's peak year Amount Records
2021 General $260 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Susan Boyer
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Susan Boyer were reported at $0. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Susan Boyer Psychiatry median Middle half National median
2019 $0 $184 $59–$605 $163
2020 $0 $119 $36–$372 $114
2021 $260 $143 $43–$576 $132
2022 $0 $153 $50–$590 $149
2023 $0 $170 $56–$651 $160
2024 $0 $179 $57–$673 $164
2025 $0 $180 $58–$685 $169

Breakdown

Who paid General payments · program year 2021
  1. AbbVie, Inc. $140 15 payments
  2. Janssen Pharmaceuticals, Inc $97 3 payments
  3. Jazz Pharmaceuticals Inc. $23 1 payment

Every payment, record by record

What the payments were for General payments · program year 2021
  1. Food and Beverage $260 19 payments
Products named General payments · program year 2021
  1. VRAYLAR $140 15 payments
  2. SPRAVATO $97 3 payments
  3. INVEGA SUSTENNA $72 2 payments
  4. INVEGA $72 2 payments
  5. INVEGA TRINZA $72 2 payments
  6. SUNOSI $23 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 56 drugs

Part D claims

2,057

Median for Psychiatry: 574

Drug cost

$285,557

Median for Psychiatry: $27,624

Branded share of claims

24.6%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Abilify Maintena Aripiprazole Brand 19 $60,713
Caplyta Lumateperone Tosylate Brand 37 $59,662
Rexulti Brexpiprazole Brand 15 $22,195
Vraylar Cariprazine Hcl Brand 16 $22,150
Parnate Tranylcypromine Sulfate Brand 11 $16,828
Trintellix Vortioxetine Hydrobromide Brand 12 $12,114
Savella Milnacipran Hcl Brand 21 $11,508
Fetzima Levomilnacipran Hcl Brand 21 $10,117
Belsomra Suvorexant Brand 15 $9,237
Fluphenazine Hcl Generic 21 $7,935

The 10 drugs with the highest cost, of 56 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 3 billing codes

Paid by Medicare

$63,791

Medicare's payments for the services billed

Medicare patients

72

Average age 65

Services billed

1,205

52 women, 20 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 75%
High blood pressure 58%
Arthritis 49%
Diabetes 26%
Ischemic heart disease 25%
Chronic kidney disease 22%
Cancer 15%
Osteoporosis 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

19 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2021

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record